TALIPEXOLE DIHYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C10H15N3S.2ClH
Molecular Weight	282.233
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.Cl.NC1=NC2=C(CCN(CC=C)CC2)S1

InChI

InChIKey=DPQAXNSOFFYKDS-UHFFFAOYSA-N

InChI=1S/C10H15N3S.2ClH/c1-2-5-13-6-3-8-9(4-7-13)14-10(11)12-8;;/h2H,1,3-7H2,(H2,11,12);2*1H

HIDE SMILES / InChI

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C10H15N3S
Molecular Weight	209.311
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8842679

Talipexole is a D2 receptor agonist which was marketed in June 1996 in Japan for the treatment of Parkinson's disease. Clinical trials with talipexole in patients with Parkinson's disease demonstrated statistically significant improvements from baseline for parkinsonian symptoms including akinesia, rigidity, tremor and gait disturbances.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Dopamine D2 receptor 297 Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	5.8 null [pKi]
Dopamine D3 receptor 91 Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/10455328	Agonist 2678	7.0 null [pKi]
Alpha-2a adrenergic receptor 63 Target ID: CHEMBL1867 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.43 null [pKi]
Alpha-2b adrenergic receptor 27 Target ID: CHEMBL1942 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.09 null [pKi]
Alpha-2c adrenergic receptor 37 Target ID: CHEMBL1916 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	7.37 null [pKi]
Dopamine D4 receptor 71 Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/12388666	Agonist 2678	6.48 null [pKi]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic schizophrenia 6 Sources: http://www.ncbi.nlm.nih.gov/pubmed/8102551	Primary		Preclinical	Unknown Approved Use Unknown
Parkinson's disease 226 Sources: http://link.springer.com/article/10.2165/00023210-199707050-00007	Primary		Phase II 1132	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole.	2001 Apr 6	11301060
Modulation of ligand responses by coupling of alpha(2A)-adrenoceptors to diverse G(alpha)-proteins.	2001 May 1	11301041
Influence of sildenafil on central dopamine-mediated behaviour in male rats.	2002 Feb 15	11895101
Impaired endothelial alpha-2 adrenergic receptor-mediated vascular relaxation in the fructose-fed rat.	2002 Mar	12047035
Inhibitory effects of D2 agonists by striatal injection on excessive release of dopamine and hyperactivity induced by Bay K 8644 in rats.	2003	12732253
Repeated administration of methamphetamine causes hypersensitivity of D2 receptor in rat ventral tegmental area.	2003 Aug 21	12873735
Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor.	2004 Oct 11	15473914
Drug treatment of Parkinson's disease.	2004 Sep	22033779
Antagonistic activity of ascorbic acid (vitamin C) on dopaminergic modulation: apomorphine-induced stereotypic behavior in mice.	2006	16569938
Pre-junctional alpha2-adrenoceptors modulation of the nitrergic transmission in the pig urinary bladder neck.	2007	17266136
alpha2-adrenoceptor agonists as nasal decongestants.	2007	16809058
Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?	2008 Mar	17680806
Bromocriptine, a dopamine D(2) receptor agonist with the structure of the amino acid ergot alkaloids, induces neurite outgrowth in PC12 cells.	2008 Nov 19	18835264
Pharmacokinetic profile of talipexole in healthy volunteers is not altered when it is co-administered with Madopar (co-beneldopa).	2009 Jun	19646081
The neuroprotective effect of talipexole from paraquat-induced cell death in dopaminergic neuronal cells.	2010 Dec	20673835
Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproduction.	2010 May	21209752
[Dopaminergic neuroprotection and reconstruction of neural network tiara].	2010 Oct	20930477

Patents

Sample Use Guides

In Vivo Use Guide

Initially 0.2 or 0-4 mg/day, increased by 0.4 mg every week (usual maintenance dosage 1.2 to 3.6 mg/day) Below 0.8 mg/day, once a day; 0.8 to 1.2 mg/day, twice a day; over 1.2 mg/day, 3 times a day

Route of Administration: Oral

In Vitro Use Guide

Talipexole at low concentration (0.1-1 mM) significantly inhibited the accumulation of cytochrome c in the cytosolic fraction of human neuroblastoma SH-SY5Y cells

Substance Class	Chemical Created by `admin` on `Fri Dec 15 15:28:52 UTC 2023` Edited by `admin` on `Fri Dec 15 15:28:52 UTC 2023`
Record UNII	9R6E1D8H1O
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALIPEXOLE DIHYDROCHLORIDE

Common Name

English

TALIPEXOLE HYDROCHLORIDE

Common Name

English

TALIPEXOLE DIHYDROCHLORIDE [MI]

Common Name

English

Talipexole hydrochloride [WHO-DD]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [JAN]

Common Name

English

TALIPEXOLE HYDROCHLORIDE [MART.]

Common Name

English

TALIPEXOLE HCL

Common Name

English

Code System Code Type Description

CAS

36085-73-1